Literature DB >> 19371811

Bisphosphonates--role in cancer therapies.

Bhoomi Mehrotra1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371811     DOI: 10.1016/j.joms.2009.01.012

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


× No keyword cloud information.
  4 in total

1.  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Evangelos Terpos
Journal:  Support Care Cancer       Date:  2009-07-30       Impact factor: 3.603

2.  Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.

Authors:  Matthew Cozin; Bradley M Pinker; Kimberley Solemani; Jeremy M Zuniga; Stephen C Dadaian; Serge Cremers; Regina Landesberg; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2011-07-31       Impact factor: 1.895

3.  Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation.

Authors:  Joseph R Tucci; Henry G Bone; Guoqin Su; Monique Tan; Zafer E Ozturk; Paul Aftring
Journal:  Ther Adv Endocrinol Metab       Date:  2015-08       Impact factor: 3.565

4.  Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.

Authors:  Marco Mozzati; Germana Martinasso; Marina Maggiora; Matteo Scoletta; Marta Zambelli; Stefano Carossa; Manuela Oraldi; Giuliana Muzio; Rosa Angela Canuto
Journal:  Clin Oral Investig       Date:  2012-08-03       Impact factor: 3.573

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.